You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to optimize the flow of blood and oxygen to tissues. Increasing the bioavailability of NO should provide therapeutic benefit in the treatment of many diseases ascribed to insufficient NO bioavailability. A ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

    SBC: VASCULOX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die while waitlisted for organs. Current practice involves donor preconditioning to stabilize organs and tissues for transplant in attempts to increase the supply of donor organs acceptable for transpl ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Adjunctive Use of Apyrase to Fibrinolytic Therapy

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I gran ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Developing an Evidence-Based Intervention Planning System for Obesity Prevention

    SBC: TRANSTRIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): To increase the effectiveness of chronic disease prevention and health promotion interventions, researchers and practitioners must work collaboratively to ensure that evidence-based approaches are translated into publicly accessible tools and resources. To disseminate evidence-based intervention strategies, it is essential to summarize the associated processes, ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. A Therapeutic Agent for Radiation-induced Lung Fibrosis

    SBC: AUXAGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lung fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and excessive deposition of extracellular matrix proteins (ECM) in lung parenchyma. Globally, five million people are affected by lung fibrosis. In the U.S. alone, 200,000 suffer from this disease. Of these m ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid, Low-Cost System for Detection of Bacterial Contamination of Blood Pla--OLD

    SBC: SOFTRAY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This STTR Phase I project will prove the concept for a low-cost, rapid system for detecting bacterial contamination in platelet concentrates, in minutes and not days, with cost/performance equal to accepted testing methodologies. Though the US has one of the safest blood supplies in the world, significant danger exists from the transfusion of blood products con ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Efficacy of Instrument-Assisted Manipulation Determined by an Animal Model

    SBC: ACTIVATOR METHODS INTERNATIONAL, LTD            Topic: N/A

    DESCRIPTION (provided by applicant): Neural responses to pain and injury as well as to various means of analgesia have profound implications as their regulation ultimately can be shown to affect the course of inflammation and thus become a matter of considerable interest. The ultimate goal is to identify and reveal the mechanisms by which the most conservative means of producing long-lasting analg ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacologic treatment of thromboembolism

    SBC: EVAS THERAPEUTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of arterial and venous thrombosis. The limitations of currently approved anticoagulant drugs have prompted the search for new anticoagulants with better pharmacological profiles. EVAS Therapeutics, LLC ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. A Low Cost Microarray for Population-Scale AIDS Risk Analysis: The AIDS Chip

    SBC: GENOMICS USA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): There is rapidly growing HIV literature, which has discovered a set of inherited genetic differences which can predict: a) the fraction of an infected population who will progress slowly, or never progress to AIDS symptoms (the so-called Elite Controllers), or b) the fraction of an infected population who will develop a dose limiting, Stevens-Johnson like infla ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Sensitive Microarray Slides Using Silica Colloidal Crystals

    SBC: BIOVIDRIA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Microarrays have become indispensable tools in research and medicine. DNA microarrays are established as research tools, and they are expected to grow into clinical diagnostics. Higher sensitivity would advance this transition, while also benefiting research. Proteins report more directly on the biology than does DNA or mRNA, protein microarrays have now become ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government